Literature DB >> 26155429

Implications of understanding the signaling, cellular, and cytotoxic mechanisms afforded by afucosylated antibodies.

Scot D Liu1, John B Lowe1.   

Abstract

Afucosylated antibodies potentiate natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) by enhancing signaling pathways and cellular processes, which in turn, increases cytotoxic potential. Importantly, a better understanding of these processes and properties will aid in exploiting them to help design therapeutic antibodies and strategies that may be of the greatest benefit to patients.

Entities:  

Keywords:  afucosylated therapeutic antibodies; antibody-dependent cellular cytotoxicity; cellular processes; natural killer cells; obinutuzumab; rituximab; signaling; trastuzumab

Year:  2015        PMID： 26155429      PMCID： PMC4485832          DOI： 10.1080/2162402X.2015.1009288

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

Review 1.  Trastuzumab--mechanism of action and use in clinical practice.

Authors:  Clifford A Hudis
Journal:  N Engl J Med       Date:  2007-07-05       Impact factor: 91.245

Review 2.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

3.  Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC.

Authors:  Scot D Liu; Cecile Chalouni; Judy C Young; Teemu T Junttila; Mark X Sliwkowski; John B Lowe
Journal:  Cancer Immunol Res       Date:  2014-11-11       Impact factor: 11.151

4.  Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.

Authors:  Teemu T Junttila; Kathryn Parsons; Christine Olsson; Yanmei Lu; Yan Xin; Julie Theriault; Lisa Crocker; Oliver Pabonan; Tomasz Baginski; Gloria Meng; Klara Totpal; Robert F Kelley; Mark X Sliwkowski
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

5.  Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors:  R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

6.  Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity.

Authors:  Sylvia Herter; Martina C Birk; Christian Klein; Christian Gerdes; Pablo Umana; Marina Bacac
Journal:  J Immunol       Date:  2014-01-31       Impact factor: 5.422

7.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Authors:  Ekkehard Mössner; Peter Brünker; Samuel Moser; Ursula Püntener; Carla Schmidt; Sylvia Herter; Roger Grau; Christian Gerdes; Adam Nopora; Erwin van Puijenbroek; Claudia Ferrara; Peter Sondermann; Christiane Jäger; Pamela Strein; Georg Fertig; Thomas Friess; Christine Schüll; Sabine Bauer; Joseph Dal Porto; Christopher Del Nagro; Karim Dabbagh; Martin J S Dyer; Sibrand Poppema; Christian Klein; Pablo Umaña
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

8.  Myeloid cells as effector cells for monoclonal antibody therapy of cancer.

Authors:  Rens Braster; Tom O'Toole; Marjolein van Egmond
Journal:  Methods       Date:  2013-06-27       Impact factor: 3.608

Review 9.  A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.

Authors:  James D Mellor; Michael P Brown; Helen R Irving; John R Zalcberg; Alexander Dobrovic
Journal:  J Hematol Oncol       Date:  2013-01-04       Impact factor: 17.388
  9 in total
  1 in total

1.  The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.

Authors:  Pauline Estupina; Alexandre Fontayne; Jean-Marc Barret; Nathalie Kersual; Olivier Dubreuil; Marion Le Blay; Alexandre Pichard; Marta Jarlier; Martine Pugnière; Maëva Chauvin; Thierry Chardès; Jean-Pierre Pouget; Emmanuel Deshayes; Alexis Rossignol; Toufik Abache; Christophe de Romeuf; Aurélie Terrier; Lucie Verhaeghe; Christine Gaucher; Jean-François Prost; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Oncotarget       Date:  2017-06-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.